Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

STREAM (Strategic Reperfusion Early After Myocardial Infarction). Comparison of the Efficacy and Safety of a Strategy of Early Fibrinolytic Treatment With Tenecteplase and Additional Antiplatelet and Antithrombin Therapy Followed by Catheterisation Within 6-24 Hours or Rescue Coronary Intervention Versus a Strategy of Standard Primary PCI in Patients With Acute Myocardial Infarction Within 3 Hours of Onset of Symptoms.

Next Previous
X
Search
Trial Profile

STREAM (Strategic Reperfusion Early After Myocardial Infarction). Comparison of the Efficacy and Safety of a Strategy of Early Fibrinolytic Treatment With Tenecteplase and Additional Antiplatelet and Antithrombin Therapy Followed by Catheterisation Within 6-24 Hours or Rescue Coronary Intervention Versus a Strategy of Standard Primary PCI in Patients With Acute Myocardial Infarction Within 3 Hours of Onset of Symptoms.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 17 Dec 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tenecteplase (Primary) ; Aspirin; Clopidogrel; Enoxaparin sodium; Enoxaparin sodium
  • Indications Cardiovascular disorders; Myocardial infarction
  • Focus Adverse reactions; Proof of concept; Registrational; Therapeutic Use
  • Acronyms STREAM

    • Most Recent Events

    • 11 Mar 2013 Data presented at the American College of Cardiology 62nd Annual Scientific Sessions and Expo, according to a Boehringer Ingelheim media release.
    • 10 Mar 2013 Primary endpoint `composite of all-cause mortality, cardiogenic shock, congestive heart failure and recurrent myocardial infarction' has been met.
    • 10 Mar 2013 Rationale, trial design and results presented at a late-breaking clinical trial session at the 62nd Annual Scientific Session of the American College of Cardiology.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top